Efficacy and safety of once‐weekly subcutaneous semaglutide 2.4 mg for the management of overweight or obesity in Asian populations: A systematic review, meta‐analysis and meta‐regression of randomised trials

Aug 27, 2025Diabetes, obesity & metabolism

Effectiveness and safety of weekly semaglutide injections for managing overweight and obesity in Asian people

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Treatment with semaglutide 2.4 mg led to a significant reduction in body weight by 8.20% compared to placebo in Asian individuals with overweight or obesity.

Participants receiving semaglutide 2.4 mg experienced greater reductions in waist circumference (6.47 cm) and body mass index (3.22 kg/m²) than those on placebo.
Systolic blood pressure decreased by 3.46 mmHg in the semaglutide group compared to placebo.
A higher percentage of individuals treated with semaglutide achieved weight loss exceeding 5%, 10%, and 15% compared to those receiving placebo.
Gastrointestinal symptoms were the most frequently reported side effects, typically mild to moderate and self-limiting.
The included studies showed a low risk of bias, indicating reliable results for the effectiveness of semaglutide in this population.

AI simplified

AIMS: The rising prevalence of overweight and obesity among Asian populations poses a critical public health concern. Semaglutide 2.4 mg, a glucagon-like peptide-1 receptor agonist, has demonstrated promising weight-reduction effects in global populations, but its efficacy and safety profile in Asians remain less comprehensively examined. This meta-analysis aimed to evaluate the effectiveness and tolerability of semaglutide 2.4 mg compared to placebo in Asian individuals with overweight or obesity.

MATERIALS AND METHODS: A systematic literature search was conducted in Medline, ScienceDirect, Europe pubMed central (PMC) and the Cochrane Library up to 15 June 2025. Eligible studies were randomised controlled trials (RCTs) comparing semaglutide 2.4 mg with placebo in overweight or obese Asian individuals. Risk of bias was evaluated using the Cochrane Risk of Bias v2 tool. Pooled outcomes were analysed using random-effects models to estimate mean differences (MDs) and odds ratios, and heterogeneity was assessed with the Istatistic. 2

RESULTS: Five RCTs involving 2614 participants met the inclusion criteria. All trials were deemed to have a low risk of bias. Our meta-analysis indicated that treatment with semaglutide 2.4 mg resulted in significantly greater reductions in body weight (MD: -8.20%; 95% confidence interval [CI]: -10.06 to -6.35; I = 84%), waist circumference (MD: -6.47 cm; 95% CI: -8.26 to -4.68; I = 84%), body mass index (MD: -3.22 kg/m; 95% CI: -4.01 to -2.44; I = 66%) and systolic blood pressure (MD: -3.46 mmHg; 95% CI: -5.29 to -1.62; I = 28%) compared to placebo. A higher proportion of participants in semaglutide 2.4 mg achieved weight loss exceeding 5%, 10% and 15%. Gastrointestinal symptoms were the most commonly reported adverse effects, generally mild to moderate and self-limiting. 2 2 2 2 2

CONCLUSIONS: Semaglutide 2.4 mg significantly improves weight-related and cardiometabolic outcomes in Asian adults with overweight or obesity. Further studies are warranted to assess long-term effects, real-world applicability and variability across subpopulations.

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text (XML) ↗View full text ↗

Efficacy and safety of once‐weekly subcutaneous semaglutide 2.4 mg for the management of overweight or obesity in Asian populations: A systematic review, meta‐analysis and meta‐regression of randomised trials

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief